Clinical Trial: 225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women

U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07772375) titled '225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women' on Aug. 13.

Brief Summary: This randomized controlled trial will compare two starting doses of follicle-stimulating hormone (FSH), 225 IU and 300 IU, during progestin-primed ovarian stimulation (PPOS) in women undergoing in vitro fertilization (IVF) who have a good reproductive prognosis. Participants will be randomly assigned to receive either 225 IU or 300 IU of FSH at the start of ovarian stimulation. The study will evaluate whether the starting FSH dose affects oocyte and embryo outcomes, with blastocyst formation as the primary outcome. Other outcomes will...